NYSEAMERICAN:RNN - Rexahn Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.5355 -0.04 (-6.95 %) (As of 02/22/2019 04:00 PM ET)Previous Close$0.5355Today's Range$0.50 - $0.565052-Week Range$0.50 - $2.38Volume1.97 million shsAverage Volume1.42 million shsMarket Capitalization$20.09 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland. Receive RNN News and Ratings via Email Sign-up to receive the latest news and ratings for RNN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:RNN Previous SymbolNYSEMKT:RNN CUSIPN/A CIK1228627 Webrexahn.comcms Phone+1-240-2685300Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees17 Outstanding Shares37,521,000Market Cap$20.09 million Next Earnings Date3/11/2019 (Estimated) OptionableOptionable Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Frequently Asked Questions What is Rexahn Pharmaceuticals' stock symbol? Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "RNN." How were Rexahn Pharmaceuticals' earnings last quarter? Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) released its quarterly earnings data on Monday, November, 5th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.00. View Rexahn Pharmaceuticals' Earnings History. When is Rexahn Pharmaceuticals' next earnings date? Rexahn Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Rexahn Pharmaceuticals. What price target have analysts set for RNN? 4 Wall Street analysts have issued 1-year target prices for Rexahn Pharmaceuticals' shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Rexahn Pharmaceuticals' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 1,580.7% from the stock's current price. View Analyst Price Targets for Rexahn Pharmaceuticals. What is the consensus analysts' recommendation for Rexahn Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rexahn Pharmaceuticals in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rexahn Pharmaceuticals. What are Wall Street analysts saying about Rexahn Pharmaceuticals stock? Here are some recent quotes from research analysts about Rexahn Pharmaceuticals stock: 1. According to Zacks Investment Research, "REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. " (1/25/2019) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and price target of $17. The majority of contribution to our valuation comes from RX-3117, which represents 72% of our $17 price target. The remaining valuation comes from RX-5902 (Supinoxin) for triple negative breast cancer. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (1/15/2019) Has Rexahn Pharmaceuticals been receiving favorable news coverage? News stories about RNN stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Rexahn Pharmaceuticals earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. Are investors shorting Rexahn Pharmaceuticals? Rexahn Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,257,406 shares, an increase of 49.5% from the January 15th total of 841,221 shares. Based on an average trading volume of 2,249,582 shares, the short-interest ratio is currently 0.6 days. Currently, 3.4% of the shares of the stock are sold short. View Rexahn Pharmaceuticals' Current Options Chain. Who are some of Rexahn Pharmaceuticals' key competitors? Some companies that are related to Rexahn Pharmaceuticals include Protalix Biotherapeutics (PLX), Promis Neurosciences (PMN), Ampio Pharmaceuticals (AMPE), Helix Biopharma (HBP), Pediapharm (PDP), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Antibe Therapeutics (ATE), Imugene (IMU), Noxopharm (NOX), Asterias Biotherapeutics (AST), Immunoprecise Antibodies (IPA), Oncolytics Biotech (ONC), Biotron (BIT) and Zelda Therapeutics (ZLD). What other stocks do shareholders of Rexahn Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Medallion Financial (MFIN), OncoSec Medical (ONCS), CytRx (CYTR), Madrigal Pharmaceuticals (MDGL), Celsion (CLSN), Dynavax Technologies (DVAX), SLS International (SLS), Cytori Therapeutics (CYTX) and Synergy Pharmaceuticals (SGYP). Who are Rexahn Pharmaceuticals' key executives? Rexahn Pharmaceuticals' management team includes the folowing people: Dr. Ely Benaim, Chief Medical Officer (Age 58)Dr. Lisa Elizabeth Nolan, Chief Bus. Officer (Age 57)Mr. Douglas J. Swirsky C.F.A., CPA, CPA, CFA, CEO, Pres, CFO, Corp. Sec. & Director (Age 50)Dr. Madhukar H. Trivedi M.D., ConsultantDr. Andrew Eisen M.D., VP of Translational Medicine Who are Rexahn Pharmaceuticals' major shareholders? Rexahn Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include CVI Holdings LLC (4.13%). Company insiders that own Rexahn Pharmaceuticals stock include Ben Gil Price, Chang Ho Ahn, Charles Beever, Douglas J Swirsky and Lisa Nolan. View Institutional Ownership Trends for Rexahn Pharmaceuticals. Which institutional investors are buying Rexahn Pharmaceuticals stock? RNN stock was bought by a variety of institutional investors in the last quarter, including CVI Holdings LLC. Company insiders that have bought Rexahn Pharmaceuticals stock in the last two years include Ben Gil Price, Charles Beever, Douglas J Swirsky and Lisa Nolan. View Insider Buying and Selling for Rexahn Pharmaceuticals. How do I buy shares of Rexahn Pharmaceuticals? Shares of RNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Rexahn Pharmaceuticals' stock price today? One share of RNN stock can currently be purchased for approximately $0.5355. How big of a company is Rexahn Pharmaceuticals? Rexahn Pharmaceuticals has a market capitalization of $20.09 million. Rexahn Pharmaceuticals employs 17 workers across the globe. What is Rexahn Pharmaceuticals' official website? The official website for Rexahn Pharmaceuticals is https://rexahn.com/cms/. How can I contact Rexahn Pharmaceuticals? Rexahn Pharmaceuticals' mailing address is 15245 Shady Grove Rd Ste 455, ROCKVILLE, MD 20850-7203, United States. The company can be reached via phone at +1-240-2685300. MarketBeat Community Rating for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 286 (Vote Outperform)Underperform Votes: 228 (Vote Underperform)Total Votes: 514MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe RNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2019 by MarketBeat.com StaffFeatured Article: What are the Benefits of Index Funds?